Serum osteoprotegerin is an independent marker of central arterial stiffness as assessed using carotid-femoral pulse wave velocity in hemodialysis patients: a cross sectional study.
Arterial stiffness
Carotid-femoral pulse wave velocity
Hemodialysis
Osteoprotegerin
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
23 05 2019
23 05 2019
Historique:
received:
01
01
2019
accepted:
06
05
2019
entrez:
25
5
2019
pubmed:
28
5
2019
medline:
1
9
2020
Statut:
epublish
Résumé
Cardiovascular morbidity and mortality are highly prevalent in patients with end-stage renal disease, and osteoprotegerin (OPG) may be an important link between bone loss and vascular calcification. This study was conducted to evaluate the relationship between central arterial stiffness and serum OPG levels in hemodialysis (HD) patients. Blood samples were collected from 120 HD patients, and the carotid-femoral pulse wave velocity (cfPWV) value was measured using a validated tonometry system. The cfPWV value of > 10 m/s was used to define the high artery stiffness group. Serum OPG levels were analyzed categorically into tertiles. Of the 120 HD patients, 53 (44.2%) were defined as the high arterial stiffness group, who had higher values of systolic blood pressure (p = 0.038), serum calcium (p = 0.007), and OPG (p < 0.001) levels and a higher prevalence of diabetes mellitus (DM, p = 0.001). Increasing tertiles of serum OPG levels were significantly associated with greater height (p = 0.011), male gender (p = 0.008), higher cfPWV values (p = 0.020), and lower intact parathyroid hormone (iPTH, p = 0.049) levels. Multivariable linear regression analysis showed that cfPWV value was independently associated with DM (β = 1.83, p = 0.008) and increasing tertiles of serum OPG levels (β = 0.89 and 1.63 for tertile 2 and tertile 3, respectively, p for trend = 0.035) in HD patients. Multivariable logistic regression analysis revealed that, in addition to age, DM, low iPTH levels, and high serum calcium levels, increasing tertiles of serum OPG levels (OR = 5.34 for tertile 2; OR = 7.06 for tertile 3; p for trend = 0.002) were an independent predictor of high arterial stiffness in HD patients. Serum calcium levels positively correlated with cfPWV value only in the highest OPG tertile group (r = 0.408, p = 0.009). A positive association was detected between serum OPG levels and central arterial stiffness in HD patients, and patients with high serum OPG levels may have greater influence of calcium load on central arterial stiffening.
Sections du résumé
BACKGROUND
Cardiovascular morbidity and mortality are highly prevalent in patients with end-stage renal disease, and osteoprotegerin (OPG) may be an important link between bone loss and vascular calcification. This study was conducted to evaluate the relationship between central arterial stiffness and serum OPG levels in hemodialysis (HD) patients.
METHODS
Blood samples were collected from 120 HD patients, and the carotid-femoral pulse wave velocity (cfPWV) value was measured using a validated tonometry system. The cfPWV value of > 10 m/s was used to define the high artery stiffness group. Serum OPG levels were analyzed categorically into tertiles.
RESULTS
Of the 120 HD patients, 53 (44.2%) were defined as the high arterial stiffness group, who had higher values of systolic blood pressure (p = 0.038), serum calcium (p = 0.007), and OPG (p < 0.001) levels and a higher prevalence of diabetes mellitus (DM, p = 0.001). Increasing tertiles of serum OPG levels were significantly associated with greater height (p = 0.011), male gender (p = 0.008), higher cfPWV values (p = 0.020), and lower intact parathyroid hormone (iPTH, p = 0.049) levels. Multivariable linear regression analysis showed that cfPWV value was independently associated with DM (β = 1.83, p = 0.008) and increasing tertiles of serum OPG levels (β = 0.89 and 1.63 for tertile 2 and tertile 3, respectively, p for trend = 0.035) in HD patients. Multivariable logistic regression analysis revealed that, in addition to age, DM, low iPTH levels, and high serum calcium levels, increasing tertiles of serum OPG levels (OR = 5.34 for tertile 2; OR = 7.06 for tertile 3; p for trend = 0.002) were an independent predictor of high arterial stiffness in HD patients. Serum calcium levels positively correlated with cfPWV value only in the highest OPG tertile group (r = 0.408, p = 0.009).
CONCLUSION
A positive association was detected between serum OPG levels and central arterial stiffness in HD patients, and patients with high serum OPG levels may have greater influence of calcium load on central arterial stiffening.
Identifiants
pubmed: 31122190
doi: 10.1186/s12882-019-1374-2
pii: 10.1186/s12882-019-1374-2
pmc: PMC6533647
doi:
Substances chimiques
Biomarkers
0
Osteoprotegerin
0
TNFRSF11B protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
184Références
Arterioscler Thromb Vasc Biol. 2005 May;25(5):932-43
pubmed: 15731494
Genes Dev. 1998 May 1;12(9):1260-8
pubmed: 9573043
Eur Heart J. 2013 Jul;34(28):2159-219
pubmed: 23771844
J Am Soc Nephrol. 1998 Dec;9(12 Suppl):S16-23
pubmed: 11443763
Lancet. 2013 Jul 27;382(9889):339-52
pubmed: 23727170
J Clin Hypertens (Greenwich). 2014 Apr;16(4):301-8
pubmed: 24640954
Pharmacol Ther. 2018 Feb;182:115-132
pubmed: 28867452
Diabetes Care. 2003 Jul;26(7):2133-8
pubmed: 12832325
Am J Kidney Dis. 2002 Mar;39(3):525-32
pubmed: 11877571
J Am Soc Nephrol. 2004 Jul;15(7):1943-51
pubmed: 15213285
J Am Soc Nephrol. 2008 Feb;19(2):213-6
pubmed: 18094365
J Am Soc Nephrol. 2001 Oct;12(10):2117-24
pubmed: 11562410
Eur Heart J. 2006 Nov;27(21):2588-605
pubmed: 17000623
JAMA. 2009 Oct 28;302(16):1782-9
pubmed: 19861670
Korean J Intern Med. 2013 Nov;28(6):668-77
pubmed: 24307842
Hypertension. 2001 Sep;38(3):434-8
pubmed: 11566918
Nephrol Dial Transplant. 2009 Oct;24(10):3157-62
pubmed: 19491380
J Hum Hypertens. 2001 Oct;15(10):693-700
pubmed: 11607799
Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201
pubmed: 14520607
Am J Hypertens. 2010 Jun;23(6):586-91
pubmed: 20224558
J Am Coll Cardiol. 2006 May 2;47(9):1850-7
pubmed: 16682312
BMC Nephrol. 2013 Jun 12;14:122
pubmed: 23758931
Clin Endocrinol (Oxf). 2005 Nov;63(5):594-8
pubmed: 16268814
J Am Soc Nephrol. 2006 Jan;17(1):262-70
pubmed: 16280472
Nephrol Dial Transplant. 2016 Jan;31(1):31-9
pubmed: 25916871
J Am Soc Nephrol. 2008 Sep;19(9):1827-35
pubmed: 18480316
Clin J Am Soc Nephrol. 2011 Nov;6(11):2612-9
pubmed: 21940840
Trends Mol Med. 2009 Sep;15(9):405-16
pubmed: 19733120
Curr Osteoporos Rep. 2015 Dec;13(6):372-80
pubmed: 26409849
Am J Hypertens. 2001 May;14(5 Pt 1):475-86
pubmed: 11368471
Kidney Int. 2017 Jul;92(1):26-36
pubmed: 28646995
Am J Hypertens. 2006 Sep;19(9):889-96
pubmed: 16942929